{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=17", "query": { "intervention": "Chemotherapeutic Agent", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:42:20.798Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02010567", "title": "Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-12", "completion_date": "2019-06-25", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 6, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02010567" }, { "nct_id": "NCT05334329", "title": "Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Antineoplastic Immune Cell", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-07-20", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05334329" }, { "nct_id": "NCT05283720", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride [HCl]", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2022-06-14", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 18, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283720" }, { "nct_id": "NCT05123482", "title": "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Biliary Tract Carcinoma", "Ovarian Cancer", "Endometrial Cancer", "Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD8205", "type": "DRUG" }, { "name": "AZD8205 and AZD2936 (Rilvegostomig)", "type": "DRUG" }, { "name": "AZD8205 and AZD5305 (saruparib)", "type": "DRUG" }, { "name": "AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)", "type": "DRUG" }, { "name": "AZD8205 in combination with AZD9574", "type": "DRUG" }, { "name": "AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2021-10-18", "completion_date": "2027-09-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123482" }, { "nct_id": "NCT00423410", "title": "A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "EPC2407 (crinobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpiCept Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-12", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2009-09-10", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • San Diego, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423410" }, { "nct_id": "NCT00069745", "title": "Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer", "Hormone Refractory Prostate Cancer" ], "interventions": [ { "name": "Satraplatin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agennix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2003-09", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 105, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069745" }, { "nct_id": "NCT04214886", "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Acute Lymphoblastic Leukemia, Adult", "B-cell Lymphoma Refractory", "B-cell Lymphoma Recurrent" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CD19-CD34 CAR transduced T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-12-31", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214886" }, { "nct_id": "NCT03030417", "title": "Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "LMP744", "type": "DRUG" }, { "name": "Ondansetron", "type": "OTHER" }, { "name": "Olanzapine", "type": "OTHER" }, { "name": "Lorazepam", "type": "OTHER" }, { "name": "Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate", "type": "OTHER" }, { "name": "Loperamide", "type": "OTHER" }, { "name": "Diphenhydramine", "type": "OTHER" }, { "name": "Steroid", "type": "OTHER" }, { "name": "Epinephrine", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-02-27", "completion_date": "2023-10-12", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Pittsburgh, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030417" }, { "nct_id": "NCT05171335", "title": "Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Transcatheter Arterial Chemoembolization", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-08-20", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05171335" }, { "nct_id": "NCT00499616", "title": "Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "12 Years", "sex": "ALL", "summary": "Up to 12 Years" }, "enrollment_count": 464, "start_date": "2007-10-08", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-10-15T04:42:20.798Z", "location_count": 166, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499616" } ] }